AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.
研究兴趣

论文共 185 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
11P Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01
H. Hayashi, Y. Goto, H.A. Yu, P.A. Jänne,J.C-H. Yang, M. Reck, K. Yoh,S-H. Lee, L. Paz-Ares, B. Besse, P. Bironzo,D-W. Kim,
ESMO Open (2024)
引用0浏览0引用
0
0
1319MO Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
M.L. Johnson, P.A. Jänne, Y. Goto, K. Yoh,S-H. Lee, L. Paz-Ares, B. Besse,S. Novello, H. Hayashi,D-W. Kim,T. John, S.C-H. Kao,
Annals of Oncology (2023): S760-S761
引用0浏览0引用
0
0
1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Y-G. Lee,J.S. Ahn,M-J. Ahn,J.H. Kang, R.A. Soo, T. Reungwetwattana,J.C-H. Yang, I. Cicin,D-W. Kim, B. Zaric, H. Go, K.C. Jahng,
Annals of Oncology (2023): S776-S776
引用0浏览0引用
0
0
1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
B.J. Solomon, A. Drilon, J.J. Lin, L. Bazhenova, K. Goto,J. De Langen,D-W. Kim, J. Wolf, C. Springfeld, S. Popat,D.W-T. Lim, C.S. Baik,
Annals of Oncology (2023): S787-S788
引用0浏览0引用
0
0
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
M. Brandão, J.T.J.N. Hiltermann, E. Wauters, B.J. Solomon,E. Castanon Alvarez, E. Felip, E.H. Gort, H. Izumi,D-W. Kim, L. Paz-Ares, K.S. Rohrberg, L. Steinbusch,
Annals of Oncology (2023): S822-S823
引用0浏览0引用
0
0
Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
S. Lee, Y. M. Seol,D. W. Kim
ANNALS OF ONCOLOGY (2023): S1540-S1540
引用0浏览0引用
0
0
1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
A. Schram, K. Goto,D-W. Kim, A. Hollebecque, S.Y. Rha, K. Nishino, M. Duruisseaux, K. Umemoto, J.O. Park,N. Leighl, T. Macarulla, S.V. Liu,
Annals of Oncology (2023): S756-S757
引用0浏览0引用
0
0
595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
D-W. Kim, K. Goto, A. Schram, A. Hollebecque, S.Y. Rha, K. Nishino, M. Duruisseaux, K. Umemoto, J.O. Park, N. Leighl,T. Macarulla Mercade, S.V. Liu,
Annals of Oncology (2023): S1702-S1703
引用0浏览0引用
0
0
加载更多
作者统计
  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn